MX2018016091A - Composiciones de fosfolipidos. - Google Patents

Composiciones de fosfolipidos.

Info

Publication number
MX2018016091A
MX2018016091A MX2018016091A MX2018016091A MX2018016091A MX 2018016091 A MX2018016091 A MX 2018016091A MX 2018016091 A MX2018016091 A MX 2018016091A MX 2018016091 A MX2018016091 A MX 2018016091A MX 2018016091 A MX2018016091 A MX 2018016091A
Authority
MX
Mexico
Prior art keywords
compositions
extract
modified
egg yolk
phospholipid compositions
Prior art date
Application number
MX2018016091A
Other languages
English (en)
Inventor
Hudson Colleen
Kobr Lukas
F Miknis Gregory
Monfregola Luca
Jirkovsky Pavel
Milada Zboncakova
Duex Jason
Kandasamy Pitchaimani
Staszak-Jirkovsky Jakub
Original Assignee
Machavert Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Machavert Pharmaceuticals Llc filed Critical Machavert Pharmaceuticals Llc
Publication of MX2018016091A publication Critical patent/MX2018016091A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2221/00—Applications of separation devices
    • B01D2221/10—Separation devices for use in medical, pharmaceutical or laboratory applications, e.g. separating amalgam from dental treatment residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen composiciones que implican un extracto de yema de huevo modificada para uso como un agente anti-cáncer efectivo. El extracto de yema de huevo modificada implica fracciones 5 específicas de fosfatidilcolinas y esfingomielinas modificadas y producidas de una síntesis química aplicada al extracto que produce un efecto benéfico en la inhibición del crecimiento de células cancerosas. También se describen métodos para administrar estas composiciones.
MX2018016091A 2016-06-29 2017-06-29 Composiciones de fosfolipidos. MX2018016091A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662356189P 2016-06-29 2016-06-29
US201662356197P 2016-06-29 2016-06-29
PCT/US2017/039894 WO2018005735A1 (en) 2016-06-29 2017-06-29 Phosopholipid compositions

Publications (1)

Publication Number Publication Date
MX2018016091A true MX2018016091A (es) 2019-09-16

Family

ID=60785317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016091A MX2018016091A (es) 2016-06-29 2017-06-29 Composiciones de fosfolipidos.

Country Status (13)

Country Link
US (4) US10493086B2 (es)
EP (1) EP3478296A4 (es)
JP (1) JP2019520384A (es)
KR (1) KR20190022796A (es)
CN (1) CN109414446A (es)
AU (1) AU2017290724A1 (es)
BR (1) BR112018077350A2 (es)
CA (1) CA3029419A1 (es)
IL (1) IL263838A (es)
MX (1) MX2018016091A (es)
RU (1) RU2019102212A (es)
SG (1) SG11201811776WA (es)
WO (1) WO2018005735A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109946276B (zh) * 2019-03-25 2021-04-30 遵义师范学院 一种双光子荧光探针的用途
CN111454289A (zh) * 2019-11-08 2020-07-28 苏州东南药业股份有限公司 一种二油酰磷脂酰胆碱的制备方法
CN115364111B (zh) * 2021-05-17 2024-04-02 中国医学科学院基础医学研究所 甘油磷脂类化合物在治疗肿瘤中的用途
WO2023141470A2 (en) * 2022-01-19 2023-07-27 President And Fellows Of Harvard College Immunomodulatory lipids and uses thereof
CN114894910B (zh) * 2022-03-18 2023-10-20 重庆医科大学附属第一医院 1-棕榈酰-2-花生四烯酰-sn-甘油-3-磷酸胆碱检测试剂的新用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US66354A (en) * 1867-07-02 Know all men by these presents
AU599456B2 (en) * 1986-11-28 1990-07-19 Liposome Company, Inc., The Phospholipid composition
CZ280686B6 (cs) 1992-04-07 1996-04-17 Tomáš Vojkovský N-acylované fosfolipidy typu 1-0-alkyl-sn-glycero -3-fosfoethanolaminů a způsob jejich semisyntetické přípravy a použití
US6602861B1 (en) * 1992-04-16 2003-08-05 Research Corporation Technologies, Inc. Acylated phospholipid drugs
CZ282139B6 (cs) 1995-04-03 1997-05-14 Jindřich Rndr. Drsc. Kára Způsob výroby přípravku s dieteticko-preventivním a léčebným účinkem na bázi vaječných l-O-alkyl-2-acyl-fosfatidylethanolaminů
DK1406641T3 (da) 2001-06-18 2009-05-04 Neptune Technologies & Bioress Krillekstrakter til forebyggelse og/eller behandling af cardiovaskulære sygdomme
EP1426053A1 (en) * 2002-12-03 2004-06-09 Fresenius Kabi Deutschland GmbH Use of amphiphilic lipids for reducing tumor metastasis
US7838511B2 (en) 2003-07-31 2010-11-23 The Board Of Regents Of The University Of Texas System Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
WO2006111633A2 (fr) 2005-04-18 2006-10-26 Sc Dicophar Utilisation de la lecithine comme medicament dans le traitement du psoriasis
US20140050780A1 (en) * 2010-12-23 2014-02-20 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
PL217384B1 (pl) * 2012-02-06 2014-07-31 Univ Przyrodniczy We Wrocławiu Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
JP2017505301A (ja) * 2014-01-08 2017-02-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 転移性播種を予防又は低減するための方法及び医薬組成物

Also Published As

Publication number Publication date
US20200046744A1 (en) 2020-02-13
CN109414446A (zh) 2019-03-01
AU2017290724A1 (en) 2019-01-17
WO2018005735A9 (en) 2018-02-01
EP3478296A1 (en) 2019-05-08
US10493086B2 (en) 2019-12-03
US20180028545A1 (en) 2018-02-01
CA3029419A1 (en) 2018-01-04
WO2018005735A1 (en) 2018-01-04
US20180000850A1 (en) 2018-01-04
EP3478296A4 (en) 2020-03-25
RU2019102212A (ru) 2020-07-29
SG11201811776WA (en) 2019-01-30
US11433085B2 (en) 2022-09-06
BR112018077350A2 (pt) 2019-04-09
KR20190022796A (ko) 2019-03-06
JP2019520384A (ja) 2019-07-18
US20220409641A1 (en) 2022-12-29
IL263838A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
MX2018016091A (es) Composiciones de fosfolipidos.
PH12018502429A1 (en) Antibody molecules for cancer treatment
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
BR112018006578A2 (pt) composições e métodos para juntar domínios extracelulares tipo i e tipo ii como proteínas quiméricas heterólogas
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
BR112015011830A2 (pt) compostos e seus métodos de utilização
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
SG10201810879VA (en) Pharmaceutical compounds
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MX2017003944A (es) Combinacion de un acido graso omega-3 y un inhibidor de sglt-2 para tratar enfermedades hepaticas.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2017008423A (es) Formulaciones transdérmicas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2019005925A (es) Composiciones de alergenos liquidas y metodos para la preparacion de las mismas.
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
PH12016501838A1 (en) Compounds and their methods of use
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
MX2016015533A (es) Aducto de fenil glicidil eter de maltodextrina.